Please note that UPSpace will be unavailable from Friday, 2 May at 18:00 (South African Time) until Sunday, 4 May at 20:00 due to scheduled system upgrades. We apologise for any inconvenience this may cause and appreciate your understanding.
dc.contributor.author | Sepotokele, Kamogelo M.![]() |
|
dc.contributor.author | O’Kennedy, Martha M.![]() |
|
dc.contributor.author | Wandrag, D.B.R. (Daniel)![]() |
|
dc.contributor.author | Abolnik, Celia![]() |
|
dc.date.accessioned | 2024-09-19T11:11:24Z | |
dc.date.available | 2024-09-19T11:11:24Z | |
dc.date.issued | 2023-07-20 | |
dc.description | AUTHOR CONTRIBUTIONS : Conceptualization: Kamogelo M. Sepotokele, Martha M. O’Kennedy. Data curation: Kamogelo M. Sepotokele, Celia Abolnik. Formal analysis: Kamogelo M. Sepotokele, Celia Abolnik. Funding acquisition: Celia Abolnik. Investigation: Kamogelo M. Sepotokele, Martha M. O’Kennedy, Daniel B. R. Wandrag, Celia Abolnik. Methodology: Kamogelo M. Sepotokele, Martha M. O’Kennedy, Celia Abolnik. Resources: Martha M. O’Kennedy, Celia Abolnik. Supervision: Martha M. O’Kennedy, Celia Abolnik. Writing – original draft: Kamogelo M. Sepotokele, Celia Abolnik. Writing – review & editing: Kamogelo M. Sepotokele, Martha M. O’Kennedy, Daniel B. R. Wandrag, Celia Abolnik. | en_US |
dc.description | SUPPORTING INFORMATION : FIGURE S1. Protein sequence of the synthetic gene mIBV-S2P. The murine signal peptide is highlighted in blue, the linker in magenta, and the S2 domain in grey with heptad repeat 1 in yellow, the central helix in green, and the two stabilizing proline substitutions in boldface and underlined. FIGURE S2. Protein confirmation using LC-MS/MS-based peptide sequencing of the modified IBV spike protein constructs compared in this study (A) mIBV-S2P, (B) mIBV-- S2P-IAV-H6TM/CT, and (C) mIBV-S2P-NDV-FTM/CT. The percentage sequence coverage is indicated above with several unique peptides identified with > 90% confidence. Peptides with > 95% confidence are highlighted in green, those with 50–95% confidence in yellow, and those with <50% confidence in red. No peptides were identified for the non-highlighted regions of the sequence (grey). FIGURE S3. Densitometric analysis by SDS-PAGE of partially-purified mIBV-S2P-NDV-FTM/ CT VLPs. Lane 1: SeeBluePlus2 protein ladder; Lane 2: BSA Standard 100 ng/μl; Lane 3: BSA Standard 150 ng/μl; Lane 4: BSA Standard 200 ng/μl; Lane 5: BSA Standard 250 ng/μl; Lane 6: BSA Standard 300 ng/μl; Lane 7: Dialysed VLP sample (25 μl); Lane 8: Dialysed VLP sample (10 μl); Lane 9: PageRuler Prestained protein ladder; Lane 10: Positive control (Live QX-like IBV); Lane 11: Negative control (pEAQ-HT-empty). FIGURE S4. Original uncropped, unedited SDS-PAGE of partially-purified plant-produced IBV S protein Lane 1: molecular weight marker; Lane 2: plant-expressed empty pEAQ-HT vector; Lane 3: purified live QX-like IBV strain ck/ZA/3665/11; Lanes 4–7: mIBV-S2P:M:E:N fractions 2 (lanes 4 and 6) and 3 (lanes 5 and 7) extracted in either PBS or bicine as indicated; Lanes 8–11: mIBV-S2P-IAV-H6TM/CT:M2 fractions 2 (lanes 8 and 10) and 3 (lanes 9 and 11) extracted in either PBS or bicine as indicated; Lanes 12–15: mIBV-S2P-NDV-FTM/ CT:NDV Matrix fractions 2 (lanes 12 and 14) and 3 (lanes 13 and 15) extracted in either PBS or bicine as indicated. FIGURE S5. Original uncropped, unedited Western blot (B) of partially-purified plant-produced IBV S protein (Primary antibody–IBV antisera, secondary antibody—Goat-α- Chicken IgY HRP). Lane 1: molecular weight marker; Lane 2: plant-expressed empty pEAQ-HT vector; Lane 3: purified live QX-like IBV strain ck/ZA/3665/11; Lanes 4–7: mIBV-S2P:M:E:N fractions 2 (lanes 4 and 6) and 3 (lanes 5 and 7) extracted in either PBS or bicine as indicated; Lanes 8–11: mIBV-S2P-IAV-H6TM/CT:M2 fractions 2 (lanes 8 and 10) and 3 (lanes 9 and 11) extracted in either PBS or bicine as indicated; Lanes 12–15: mIBV-S2P-NDV-FTM/CT:NDV Matrix fractions 2 (lanes 12 and 14) and 3 (lanes 13 and 15) extracted in either PBS or bicine as indicated. RAW IMAGES S1. | en_US |
dc.description.abstract | Infectious bronchitis (IB) is a highly contagious, acute respiratory disease in chickens, with a severe economic impact on poultry production globally. The rapid emergence of regional variants of this Gammacoronavirus warrants new vaccine approaches that are more humane and rapid to produce than the current embryonated chicken egg-based method used for IB variant vaccine propagation (chemically-inactivated whole viruses). The production of virus-like particles (VLPs) expressing the Spike (S) glycoprotein, the major antigen which induces neutralizing antibodies, has not been achieved in planta up until now. In this study, using the Agrobacterium-mediated Nicotiana benthamiana (tobacco plant) transient expression system, the highest levels of VLPs displaying a modified S protein of a QX-like IB variant were obtained when the native transmembrane (TM) domain and cytoplasmic tail were substituted with that of the Newcastle disease virus (NDV) fusion glycoprotein, co-infiltrated with the NDV Matrix protein. In comparison, the native IB modified S co-infiltrated with IB virus membrane, envelope and nucleocapsid proteins, or substituted with the TM and CT of an H6-subtype influenza A virus hemagglutinin glycoprotein yielded lower VLP expression levels. Strong immunogenicity was confirmed in specific pathogen free chickens immunized intramuscularly with VLPs adjuvanted with Emulsigen®-P, where birds that received doses of 5 μg or 20 μg (S protein content) seroconverted after two weeks with mean hemaggluttination inhibition titres of 9.1 and 10 log2, respectively. Plant-produced IB VLP variant vaccines are safer, more rapid and cost effective to produce than VLPs produced in insect cell expression systems or the traditional egg-produced inactivated whole virus oil emulsion vaccines currently in use, with great potential for improved IB disease control in future. | en_US |
dc.description.department | Production Animal Studies | en_US |
dc.description.librarian | am2024 | en_US |
dc.description.sdg | SDG-02:Zero Hunger | en_US |
dc.description.sdg | SDG-03:Good heatlh and well-being | en_US |
dc.description.sponsorship | The Department of Science and Innovation/National Research Foundation (DSI/NRF); and bursaries from the University of Pretoria | en_US |
dc.description.uri | https://journals.plos.org/plosone/ | en_US |
dc.identifier.citation | Sepotokele, K.M., O'Kennedy, M.M., Wandrag, D.B.R. & Abolnik, C. (2023) Optimization of infectious bronchitis virus-like particle expression in Nicotiana benthamiana as potential poultry vaccines. PLoS One 18(7): e0288970. https://DOI.org/10.1371/journal.pone.0288970. | en_US |
dc.identifier.issn | 1932-6203 (online) | |
dc.identifier.other | 10.1371/journal.pone.0288970 | |
dc.identifier.uri | http://hdl.handle.net/2263/98329 | |
dc.language.iso | en | en_US |
dc.publisher | Public Library of Science | en_US |
dc.rights | © 2023 Sepotokele et al. This is an open access article distributed under the terms of the Creative Commons Attribution License. | en_US |
dc.subject | Infectious bronchitis (IB) | en_US |
dc.subject | Gammacoronavirus | en_US |
dc.subject | Chickens | en_US |
dc.subject | Poultry production | en_US |
dc.subject | SDG-03: Good health and well-being | en_US |
dc.subject | SDG-02: Zero hunger | en_US |
dc.subject | Virus-like particle (VLP) | en_US |
dc.subject | Newcastle disease virus (NDV) | en_US |
dc.title | Optimization of infectious bronchitis virus-like particle expression in Nicotiana benthamiana as potential poultry vaccines | en_US |
dc.type | Article | en_US |